Arteriovenous

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Florida Dialysis Centers Market Size, Share & Trends Analysis Report 2023: A $1.3 Billion Market by 2030 - Escalating Demand for Dialysis Units Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Medical Devices, Health, Arteriovenous, ESRD, American Kidney Fund, Prevalence, Kidney, COVID-19, Research, History, Hemodialysis, USD, Dialysis, Medicare, Hospital, Peritoneal dialysis, Investment, Patient, DaVita Inc., Growth, Chronic kidney disease, CKD, SNF, Fistula, Medical device, Pharmaceutical industry

The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to the American Kidney Fund, Florida is home to approximately 48,215 individuals grappling with End-Stage Renal Disease (ESRD).
  • The escalating demand for dialysis units across the state of Florida emerges as a pivotal factor expected to propel market growth in the coming years.
  • As of April 2023, DaVita owns or manages more than 200 outpatient dialysis centers in Florida

Decoding Brain Arteriovenous Malformations in the Asian Population: A Chinese Neurosurgical Journal Study

Retrieved on: 
Tuesday, January 10, 2023
Natural history, AVM, Unified school district, Blood, Precision medicine, Multimodality, Microsurgery, Capital University of Medical Sciences, Arteriovenous, Brain, Artery, MATCH, Male, Vein, Patient, Bleeding, Next, Seizure, Synthetic control method, Hospital, SRS, History, Rupture, Motivation, Medical imaging, Medical device, Pharmaceutical industry

BEIJING, Jan. 10, 2023 /PRNewswire/ -- Brain arteriovenous malformation (AVM) is the abnormal entanglement of arteries and veins in the brain, which disrupts the normal flow of blood and can lead to hemorrhage, seizures, and neurological impairment in affected individuals.

Key Points: 
  • Thus, there is a need to personalize treatment protocols depending on disease severity.
  • Although multiple studies have been conducted to investigate AVMs, its natural history in the Asian population is poorly understood.
  • The study is ongoing since August 2011 and is expected to conclude in April 2032.
  • As of April 2021, 3241 patients with AVMs were enrolled as part of this study.

IN.PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Retrieved on: 
Tuesday, April 20, 2021
Medicine, Clinical medicine, Medical specialties, Fistulas, Cardiology, Restenosis, Surgery, Paclitaxel, Arteriovenous fistula, Arteriovenous, Cimino fistula, Vascular access

"Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis.

Key Points: 
  • "Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis.
  • For my patients, these durable results translate into fewer reinterventions and a better quality of life.
  • Over time, vessel restenosis limits the ability to use AV fistulae effectively.
  • The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis.

Stanford Surgeon Venita Chandra Joins Alucent Biomedical Scientific Advisory Board as Company Enters Arteriovenous Fistula Market

Retrieved on: 
Tuesday, December 8, 2020
Medical devices, Health, Surgery, Pharmaceutical, Cardiology, Biotechnology, Medicine, Clinical medicine, Renal dialysis, AVF, Arteriovenous fistula, Arteriovenous, Fistula, NVS, Avera Health, Hemodialysis, Cimino fistula

Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.

Key Points: 
  • Alucent Biomedical , a privately held medical technology company founded to transform the way vascular disease is treated, today announced Venita Chandra, M.D.
  • The company announced today it will also seek to adapt the technology for another use, the maturation and preservation of arteriovenous fistula (AVF) for hemodialysis (HD).
  • Applying the treatment at fistula creation has facilitated maturation and the promotion of outward remodeling of the AVF, Dr. Chandra said.
  • Alucent was founded by Avera Health to develop and market products using Alucent Natural Vascular Scaffolding (Alucent NVS) technology.

Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis

Retrieved on: 
Friday, October 30, 2020
Medicine, Clinical medicine, Medical specialties, Renal dialysis, Vascular access, Vascular surgery, Hemodialysis, Fistula, Arteriovenous, Catheter, Cimino fistula, Interventional radiology

SAN JUAN CAPISTRANO, Calif., Oct. 30, 2020 /PRNewswire/ --A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys Vascular Access System.

Key Points: 
  • SAN JUAN CAPISTRANO, Calif., Oct. 30, 2020 /PRNewswire/ --A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection (anastomosis) that is created with the minimally invasive Ellipsys Vascular Access System.
  • The Ellipsys System, made by Avenu Medical, creates a type of dialysis access known as a percutaneous arteriovenous fistula (pAVF) for patients with end-stage renal disease (ESRD) who require hemodialysis.
  • Dr. Mallios has published numerous studies showing the ability of the Ellipsys System to easily and safely create durable vascular access for ESRD patients.
  • The company's Ellipsys Vascular Access System is an innovative, ultrasound-guided, single-catheter endoAVF system used to percutaneously create an arteriovenous fistula for hemodialysis access.

Global Neurovascular Intervention Devices Market (2020 to 2027) - Increase in the Ageing Population Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 28, 2020
Medical devices, Health, Medical specialties, Clinical medicine, Medicine, Gross pathology, Interventional radiology, Vascular diseases, Stroke, Arteriovenous malformation, Embolization, Aneurysm, Thrombectomy, Arteriovenous

The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • Neurovascular Intervention devices global market is segmented based on products, applications and geography.
  • The products are segmented into artificial embolization devices, stents, thrombectomy devices and support devices.
  • The global neurovascular intervention markets by applications are segmented into intracranial aneurysm, ischemic stroke, arteriovenous malformation and others.

Neurovascular Devices Market to Reach $3.7 Bn, Globally, by 2027 at 5.2% CAGR: Allied Market Research

Retrieved on: 
Tuesday, September 22, 2020
Medical specialties, Interventional radiology, RTT, Embolization, Surgery, Clinical medicine, Arteriovenous malformation, Stroke, AVM, Arteriovenous, Neurovascular bundle

PORTLAND, Ore., Sept. 22, 2020 /PRNewswire/ -- Allied Market Research published a report, titled," Neurovascular Devices Market by Product (Embolization Devices, Revascularization Devices, Embolic Protection Devices, and Accessory Devices), Disease Pathology (Aneurysm, Arteriovenous Malformation (AVM), Ischemic Stroke, Stenosis, and Others): Global Opportunity Analysis and Industry Forecast, 20202027."

Key Points: 
  • PORTLAND, Ore., Sept. 22, 2020 /PRNewswire/ -- Allied Market Research published a report, titled," Neurovascular Devices Market by Product (Embolization Devices, Revascularization Devices, Embolic Protection Devices, and Accessory Devices), Disease Pathology (Aneurysm, Arteriovenous Malformation (AVM), Ischemic Stroke, Stenosis, and Others): Global Opportunity Analysis and Industry Forecast, 20202027."
  • Request for Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/2278?reqf...
    Surge in geriatric population across the globe, increasein prevalence of neurovascular diseases, and technological advancements related to neurovascular devices fuel the growth of the global neurovascular devices market.
  • The pandemic has led to delays in several elective surgical procedures, impacting the global neurovascular devices market negatively.
  • Based on geography, North America garnered the highest share in 2019, generating more than one-third of the global neurovascular devices market.

FDA Clears Innovative Angioplasty Scoring and Cutting Platform

Retrieved on: 
Thursday, June 4, 2020
Medicine, Clinical medicine, Interventional radiology, Angioplasty, Fistula, Arteriovenous, Percutaneous, Popliteal, Balloon, PTA

PARK CITY, Utah, June 4, 2020 /PRNewswire/ --Transit Scientific announced the FDA cleared the XO ScorePercutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal, and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula.

Key Points: 
  • PARK CITY, Utah, June 4, 2020 /PRNewswire/ --Transit Scientific announced the FDA cleared the XO ScorePercutaneous Transluminal Angioplasty (PTA) Scoring Sheath platform for use in iliac, ilio-femoral, popliteal, infra-popliteal, and renal arterial plus synthetic and/or native arteriovenous hemodialysis fistula.
  • Calcified, fibrous, and/or resilient stenosis may require special scoring or cutting angioplasty balloons with integrated wires or blades on the balloon.The added features focus and improve dilating force but result in large crossing profiles and limited deliverability while increasing cost and inventory.
  • "XO Score transforms regular PTA balloons into scoring and cutting systems," said Greg Method, President, Transit Scientific, Park City, Utah.
  • "Rotating struts allow clinicians to vary scoring depth without increasing device profile.Economically, XO Score offers a direct value proposition:(1) XO Score + (1) off-the-shelf PTA balloon will cost less than (1) specialty PTA scoring or cutting technology."